VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 8, 2008) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) announced today the enrolment and dosing of the first patient in a Phase III clinical trial of TectinTM, the Company’s lead product candidate, for cancer pain. This clinical trial (TEC-006) is a multicentre, randomized, double-blind and placebo-controlled trial comparing the efficacy and safety of TectinTM to placebo in approximately 120 patients with moderate to severe inadequately controlled cancer-related pain.
